National Comprehensive Cancer Network awards grants for small cell lung cancer research
Click Here to Manage Email Alerts
National Comprehensive Cancer Network’s Oncology Research Program awarded three grants to support research into small cell lung cancer.
The funding — provided through support from AstraZeneca — is intended to support projects focused on reducing gaps in care for people with limited-stage or extensive-stage small cell lung cancer.
More than 30,000 new cases of small cell lung cancer (SCLC) are diagnosed annually in the United States.
“A significant number of patients with small cell lung cancer do not receive therapy consistent with established clinical practice guidelines in both the limited- and extensive-stage settings,” Crystal S. Denlinger, MD, FACP, senior vice president and chief scientific officer of NCCN, said in a press release. “We can improve access to, and receipt of, effective care in this patient population, including enhanced use of both anticancer therapies and supportive care.”
The grant funding recipients and their research projects are:
Asrar AlAhmadi, MD, of The Ohio State University Comprehensive Cancer Center — James Cancer Hospital and Solove Research Institute — the impact of area deprivation index on clinical outcomes of small cell lung cancer;
Afshin Dowlati, MD, and Melinda Hsu, MD, of Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute — an innovative team approach to standardize SCLC care delivery across an integrated health care system; and
Salene M.W. Jones, PhD, of Fred Hutchinson Cancer Center — provider and intervention barriers to multidisciplinary, guideline-concordant care in SCLC.
A scientific review committee that included oncologists from NCCN member institutions reviewed proposals. Approximately $750,000 worth of funding will be offered across the three projects.
“AstraZeneca is committed to improving outcomes for [patients with SCLC] across all stages of the disease,” Nabil Chehab, PhD, U.S. head of medical for lung cancer at AstraZeneca, said in the release. “Our hope is this collaboration will lead us one step closer to better understanding real-world challenges to the equitable delivery of care in SCLC to ensure that no patient with SCLC is left behind.”
Collapse
Press Release
Click Here to Manage Email Alerts